The BioPharm Brief: Gene Therapy, ADCs, Big Pharma Alliances

Today’s BioPharm Brief highlights a new gene therapy trial in Pompe disease, an FDA Breakthrough Therapy designation for a B7-H4 ADC in adenoid cystic carcinoma, and a major $15.2 billion BMS–Hengrui collaboration spanning oncology, hematology, and immunology.